Tags: first | drug | approved | middle-of-night | insomniacs | Intermezzo | treatments for insomnia

First Drug Approved for Middle-of-Night Insomniacs

Monday, 28 Nov 2011 07:55 AM

For the first time, the U.S. Food and Drug Administration has approved a medication specifically designed for those who wake up in the middle of the night and cannot fall back to sleep.
Intermezzo, manufactured by Transcept Pharmaceuticals of California, is a lower-dose formulation of zolpidem, first approved in the United States in 1992 and better known as the insomnia treatment Ambien.
"This is the first time the FDA has approved a drug for this condition," the federal government agency said in a statement.
"Intermezzo should only be used when a person has at least four hours of bedtime remaining. It should not be taken if alcohol has been consumed or with any other sleep aid."
The recommended dose is 3.5 milligrams for men and half that for women, after clinical tests indicated that women cleared zolpidem from their bodies more slowly than men do.
"With this lower dose, there is less risk of a person having too much drug in the body upon waking, which can cause dangerous drowsiness and impair driving," said Robert Temple of the FDA's Center for Drug Evaluation and Research.

Copyright Relaxnews

© HealthDay

   
1Like our page
2Share
Health-News
The FDA has approved the first drug designed specifically for people who wake up in the middle of the night and can't fall back to sleep.
first,drug,approved,middle-of-night,insomniacs,Intermezzo,treatments for insomnia,zolpidem
187
2011-55-28
Monday, 28 Nov 2011 07:55 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved